Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Jawad, Mays ^a   Yu, Ning ^a   Seedhouse, Claire ^a   Tandon, Karuna ^a   Russell, Nigel H ^a,b   Pallis, Monica ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

AML CD34+CD38 cells; DNA damage response; Gemtuzumab ozogamicin Mylotarg; Tipifarnib Zarnestra

Indexed keywords

CARRIER PROTEIN; CD34 ANTIGEN; CD38 ANTIGEN; CHECKPOINT KINASE 2; GEMTUZUMAB OZOGAMICIN; HISTONE GAMMA H2AX; HISTONE H2AX; THR68 PROTEIN; TIPIFARNIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFICACY; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE SUBPOPULATION;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD34; ANTIGENS, CD38; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; FMS-LIKE TYROSINE KINASE 3; HISTONES; HUMANS; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; P-GLYCOPROTEIN; QUINOLONES; SIALIC ACID BINDING IG-LIKE LECTIN 3; SIGNAL TRANSDUCTION;

EID: 84866548149     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-431     Document Type: Article

References (50)

1. Bonnet D, Dick JE. Human acute leukemia is organised as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737. 10.1038/nm0797-730, 9212098.
2. Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S, Woll P, Mead A, Alford KA, Rout R, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011, 19(1):138-152. 10.1016/j.ccr.2010.12.012, 21251617.
3. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, Metzeler KH, Poeppl A, Ling V, Beyene J, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011, 17(9):1086-1093. 10.1038/nm.2415, 21873988.
4. Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ, Jordan CT. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A 2002, 99:16220-16225. 10.1073/pnas.252462599, 138592, 12451177.
5. Costello RT, Mallet F, Gaugler B, Sainty D, Arnoulet C, Gastaut JA, Olive D. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res 2000, 60(16):4403-4411.
6. van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S, van der Pol MA, Waisfisz Q, Ossenkoppele GJ, Schuurhuis GJ. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005, 11(18):6520-6527. 10.1158/1078-0432.CCR-05-0468, 16166428.
7. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, Yin JA, Hunter A, Goldstone AH, Wheatley K. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011, 29(4):369-377. 10.1200/JCO.2010.31.4310, 21172891.
8. Petersdorf S, Kopecky K, Stuart R, Larson R, Nevill T, Stenke L, Slovak M, Tallman M, Willman C, Erba H, et al. Preliminary results of southwest oncology group study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 2009, 114:326.
9. Burnett AK, Hills RK, Hunter AE, Milligan D, Kell WJ, Wheatley K, Yin JL, Ali S, Kjeldsen L, Bowen D, et al. The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of the UK NCRI AML16 randomized trial. ASH Annual Meeting Abstracts 2011, 118(21):582.
10. Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012, 379(9825):1508-1516. 10.1016/S0140-6736(12)60485-1, 22482940.
11. Jawad M, Seedhouse C, Mony U, Grundy M, Russell NH, Pallis M. Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia 2010, 24:74-80. 10.1038/leu.2009.199, 19776761.
12. Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, Rackoff W, Koller C, O'Brien S, Garcia-Manero G, et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003, 101(5):1692-1697. 10.1182/blood-2002-07-1973, 12411300.
13. Kurzrock R, Kantarjian HM, Blascovich MA, Bucher C, Verstovsek S, Wright JJ, Pilat SR, Cortes JE, Estey EH, Giles FJ, et al. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. Clin Cancer Res 2008, 14(2):509-514. 10.1158/1078-0432.CCR-07-1532, 18223226.
14. Fenaux P, Raza A, Mufti GJ, Aul C, Germing U, Kantarjian H, Cripe L, Kerstens R, De Porre P, Kurzrock R. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood 2007, 109(10):4158-4163. 10.1182/blood-2006-07-035725, 17264294.
15. Medeiros BC, Landau HJ, Morrow M, Lockerbie RO, Pitts T, Eckhardt SG. The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines. Leukemia 2007, 21(4):739-746.
16. Korycka A, Smolewski P, Robak T. The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro. Eur J Haematol 2004, 73(6):418-426. 10.1111/j.1600-0609.2004.00336.x, 15522064.
17. Yanamandra N, Colaco NM, Parquet NA, Buzzeo RW, Boulware D, Wright G, Perez LE, Dalton WS, Beaupre DM. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res 2006, 12(2):591-599. 10.1158/1078-0432.CCR-05-1792, 16428505.
18. Karp JE, Vener TI, Raponi M, Ritchie EK, Smith BD, Gore SD, Morris LE, Feldman EJ, Greer JM, Malek S, et al. Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood 2012, 119(1):55-63. 10.1182/blood-2011-08-370825, 22001391.
19. Jabbour E, Kantarjian H, Ravandi F, Garcia-Manero G, Estrov Z, Verstovsek S, O'Brien S, Faderl S, Thomas DA, Wright JJ, et al. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 2011, 117(6):1236-1244. 10.1002/cncr.25575, 20960519.
20. Mony U, Jawad M, Seedhouse C, Russell N, Pallis M. Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment. Leukemia 2008, 22(7):1395-1401. 10.1038/leu.2008.125, 18509353.
21. Pallis M, Syan J, Russell NH. Flow cytometric chemosensitivity analysis of blasts from patients with acute myeloblastic leukemia and myelodysplastic syndromes: the use of 7AAD with antibodies to CD45 or CD34. Cytometry 1999, 37(4):308-313. 10.1002/(SICI)1097-0320(19991201)37:4<308::AID-CYTO8>3.0.CO;2-Z, 10547616.
22. Toba K, Winton EF, Koike T, Shibata A. Simultaneous three-color analysis of the surface phenotype and DNA-RNA quantitation using 7-amino-actinomycin D and pyronin Y. J Immunol Methods 1995, 182(2):193-207. 10.1016/0022-1759(95)00050-K, 7540639.
23. Pallis M, Das-Gupta E. Flow cytometric measurement of functional and phenotypic p-glycoprotein. 2005, Totowa: Humana Press, Blumenthal RD, In, Chemosensitivity, Volume 2..
24. Broxterman HJ, Sonneveld P, Feller N, Ossenkoppele G, Wahrer DCR, Eekman CA, Schoester M, Lankelma J, Pinedo HM, Lowenberg B, et al. Quality control of multidrug resistance assays in adult acute leukaemia: correlation between assays for P-glycoprotein expression and activity. Blood 1996, 87:4809-4816.
25. Seedhouse C, Grundy M, Shang S, Ronan J, Pimblett H, Russell N, Pallis M. Impaired S-phase arrest in acute myeloid leukemia cells with a FLT3 internal tandem duplication treated with clofarabine. Clin Cancer Res 2009, 15(23):7291-7298. 10.1158/1078-0432.CCR-09-1222, 19934300.
26. Seedhouse CH, Hunter HM, Lloyd-Lewis B, Massip AM, Pallis M, Carter GI, Grundy M, Shang S, Russell NH. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. Leukemia 2006, 20(12):2130-2136. 10.1038/sj.leu.2404439, 17066094.
27. Noguera NI, Ammatuna E, Zangrilli D, Lavorgna S, Divona M, Buccisano F, Amadori S, Mecucci C, Falini B, Lo-Coco F. Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. Leukemia 2005, 19(8):1479-1482. 10.1038/sj.leu.2403846, 15973451.
28. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116(3):354-365. 10.1182/blood-2009-11-254441, 20385793.
29. Hao Q-L, Shah AJ, Thiemann FT, Smogorzewska EM, Crooks GM. A functional comparison of CD34+CD38- cells in cord blood and bone marrow. Blood 1995, 86(10):3745-3753.
30. Ikezoe T, Yang J, Nishioka C, Kojima S, Takeuchi A, Phillip Koeffler H, Yokoyama A. Inhibition of signal transducer and activator of transcription 5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34(+) /CD38(-) cells and sensitizes them to antileukemia agents. Int J Cancer 2011, 128(10):2317-2325. 10.1002/ijc.25806, 21128225.
31. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 2001, 276(45):42462-42467. 10.1074/jbc.C100466200, 11571274.
32. Rothkamm K, Kruger I, Thompson LH, Lobrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol 2003, 23(16):5706-5715. 10.1128/MCB.23.16.5706-5715.2003, 166351, 12897142.
33. Guan Y, Gerhard B, Hogge DE. Detection, Isolation and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003, 101:3142-3149. 10.1182/blood-2002-10-3062, 12468427.
34. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 2003, 102(4):1466-1473. 10.1182/blood-2003-02-0396, 12689934.
35. Wang E, Casciano CN, Clement RP, Johnson WW. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. Cancer Res 2001, 61(20):7525-7529.
36. Karp JE, Flatten K, Feldman EJ, Greer JM, Loegering DA, Ricklis RM, Morris LE, Ritchie E, Smith BD, Ironside V, et al. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood 2009, 113(20):4841-4852. 10.1182/blood-2008-08-172726, 2686135, 19109557.
37. Milyavsky M, Gan OI, Trottier M, Komosa M, Tabach O, Notta F, Lechman E, Hermans KG, Eppert K, Konovalova Z, et al. A distinctive DNA damage response in human hematopoietic stem cells reveals an apoptosis-independent role for p53 in self-renewal. Cell Stem Cell 2010, 7(2):186-197. 10.1016/j.stem.2010.05.016, 20619763.
38. Gan OI, Milyavsky M, van Delft MF, Buzina A, Kalatskaya I, Ketela T, Stein L, Moffat J, Dick JE. Genome-wide shRNA screen for DNA damage response regulators in human hematopoietic stem and progenitor cells. ASH Annual Meeting Abstracts 2011, 118(21):1289.
39. Garrett MD, Collins I. Anticancer therapy with checkpoint inhibitors: what, where and when?. Trends Pharmacol Sci 2011, 32(5):308-316. 10.1016/j.tips.2011.02.014, 21458083.
40. Lukas C, Bartkova J, Latella L, Falck J, Mailand N, Schroeder T, Sehested M, Lukas J, Bartek J. DNA damage-activated kinase Chk2 is independent of proliferation or differentiation yet correlates with tissue biology. Cancer Res 2001, 61(13):4990-4993.
41. Hauswirth AW, Florian S, Printz D, Sotlar K, Krauth MT, Fritsch G, Schernthaner GH, Wacheck V, Selzer E, Sperr WR, et al. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur J Clin Invest 2007, 37(1):73-82. 10.1111/j.1365-2362.2007.01746.x, 17181570.
42. Saito Y, Kitamura H, Hijikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S, Uchida N, Suzuki N, Sone A, Najima Y, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med 2010, 2(17):17ra19.
43. Amico D, Barbui AM, Erba E, Rambaldi A, Introna M, Golay J. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood 2003, 101(11):4589-4597. 10.1182/blood-2002-07-2311, 12576328.
44. Raponi M, Lancet JE, Fan H, Dossey L, Lee G, Gojo I, Feldman EJ, Gotlib J, Morris LE, Greenberg PL, et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 2008, 111(5):2589-2596. 10.1182/blood-2007-09-112730, 18160667.
45. Pan J, She M, Xu ZX, Sun L, Yeung SC. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells. Cancer Res 2005, 65(9):3671-3681. 10.1158/0008-5472.CAN-04-2744, 15867362.
46. Dedon PC, Salzberg AA, Xu J. Exclusive production of bistranded DNA damage by calicheamicin. Biochemistry 1993, 32(14):3617-3622. 10.1021/bi00065a013, 8466904.
47. Raponi M, Belly RT, Karp JE, Lancet JE, Atkins D, Wang Y. Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer 2004, 4:56. 10.1186/1471-2407-4-56, 516036, 15329151.
48. Walter RB, Gooley TA, van der Velden VH, Loken MR, van Dongen JJ, Flowers DA, Bernstein ID, Appelbaum FR. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007, 109(10):4168-4170. 10.1182/blood-2006-09-047399, 1885511, 17227830.
49. Morris KL, Adams JA, Liu JA. Effect of gemtuzumab ozogamicin on acute myeloid leukemia blast cells in vitro, as a single agent and combined with other cytotoxic cells. Br J Haematol 2006, 135(4):509-512. 10.1111/j.1365-2141.2006.06326.x, 17054677.
50. Jedema I, Barge RM, van der Velden VH, Nijmeijer BA, van Dongen JJ, Willemze R, Falkenburg JH. Internalization and cell cycle-dependent killing of leukemic cells by gemtuzumab ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 2004, 18(2):316-325. 10.1038/sj.leu.2403205, 14614514.